Century Therapeutics inc (IPSC) - News Archive

Century Therapeutics Unveils Ambitious Beta Islet Program Aiming to Transform Type 1 Diabetes TreatmentPharmaceutical innovation is often heralded by a blend of promise and peril, especially in a field as complex as dia...

Pioneering Advances in Cell Therapy: Century Therapeutics at the Forefront of InnovationIn a landscape where pioneering science meets unmet clinical needs, Century Therapeutics, Inc. a notable player in biotechnology, h...

Century Therapeutics, a leading cell therapy company, has presented promising interim results from their Phase 1 ELiPSE-1 study at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO). The results...

Century Therapeutics, a leading biotechnology company in the field of autoimmune diseases, is making significant strides in its pursuit of additional regulatory filings for its cutting-edge iPSC derived iNK cell therapy...

Philadelphia-based biotechnology company Century Therapeutics Inc. recently presented initial data from the CNTY-101 Phase 1 ELiPSE-1 trial at the 65th ASH Annual Meeting. The results highlight the potential for a multi...